chronic rhinosinusitis with nasal polyps
Immunology · 2021–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients (≥18 years) with severe disease, inadequate response to intranasal… | May 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy · Anaphylaxis Australia · National Allergy Council |
| mepolizumab Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients with inadequate response to intranasal corticosteroids who have undergone prior nasal polyp… | Nov 2022 | Recommended with restriction | 2 individuals Australasian Society of Clinical Immunology and Allerg |
| mepolizumab Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients with inadequate response to intranasal corticosteroids who have received at… | Nov 2021 | Not recommended | 1 individuals |
Who spoke
Australasian Society of Clinical Immunology and Allergy · Anaphylaxis Australia · National Allergy Council · Australasian Society of Clinical Immunology and Allerg
What the PBS pays
$135M in government benefit over 2024–25, across 136,025 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| mepolizumab | $84.6M |
| omalizumab | $50.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| dupilumabDupilumab for treating severe chronic rhinosinusitis with nasal polyps | TA1134 | recommended | 2026-02 |
| depemokimabDepemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) | TA1123 | terminated | 2026-01 |
| mepolizumabMepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | terminated | 2022-11 |
| omalizumabOmalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | terminated | 2021-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.